Monte Rosa Therapeutics (NASDAQ:GLUE) Price Target Raised to $34.00

Monte Rosa Therapeutics (NASDAQ:GLUE) had its price target hoisted by Guggenheim from $16.00 to $34.00 in a research report released on Thursday,Benzinga reports. Guggenheim currently has a buy rating on the stock.

GLUE has been the topic of several other reports. Cowen restated a “buy” rating on shares of Monte Rosa Therapeutics in a research note on Wednesday. Wells Fargo & Company lifted their price target on Monte Rosa Therapeutics from $10.00 to $13.00 and gave the stock an “equal weight” rating in a report on Friday, November 7th. Jefferies Financial Group restated a “buy” rating and issued a $31.00 price objective on shares of Monte Rosa Therapeutics in a research note on Wednesday. Zacks Research raised Monte Rosa Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 6th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Monte Rosa Therapeutics in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Monte Rosa Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.20.

Monte Rosa Therapeutics Stock Down 4.1%

NASDAQ GLUE opened at $24.28 on Thursday. The stock has a market cap of $1.58 billion, a P/E ratio of 75.88 and a beta of 1.60. Monte Rosa Therapeutics has a twelve month low of $3.50 and a twelve month high of $25.77. The company’s 50-day simple moving average is $16.01 and its 200 day simple moving average is $9.78.

Monte Rosa Therapeutics (NASDAQ:GLUE) last released its earnings results on Thursday, November 6th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.06. Monte Rosa Therapeutics had a net margin of 11.54% and a return on equity of 8.28%. The business had revenue of $12.77 million during the quarter, compared to analysts’ expectations of $7.37 million. Research analysts anticipate that Monte Rosa Therapeutics will post -1.49 earnings per share for the current year.

Insider Transactions at Monte Rosa Therapeutics

In related news, CEO Markus Warmuth sold 5,466 shares of the stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $23.49, for a total transaction of $128,396.34. Following the completion of the sale, the chief executive officer directly owned 618,937 shares of the company’s stock, valued at approximately $14,538,830.13. This trade represents a 0.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Squarepoint Ops LLC purchased a new position in shares of Monte Rosa Therapeutics during the second quarter worth approximately $803,000. Pallas Capital Advisors LLC bought a new position in shares of Monte Rosa Therapeutics during the 2nd quarter valued at $59,000. Bailard Inc. bought a new position in shares of Monte Rosa Therapeutics during the 2nd quarter valued at $101,000. Los Angeles Capital Management LLC bought a new stake in Monte Rosa Therapeutics in the second quarter worth $89,000. Finally, Integrated Quantitative Investments LLC purchased a new stake in Monte Rosa Therapeutics during the second quarter valued at about $160,000. Institutional investors own 79.96% of the company’s stock.

Trending Headlines about Monte Rosa Therapeutics

Here are the key news stories impacting Monte Rosa Therapeutics this week:

• Positive Sentiment: Interim Phase I data showed MRT?8102 produces deep NEK7 degradation and drove a large reduction in inflammation markers, which triggered a big intraday rally in the stock. GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug
• Positive Sentiment: Early trial readouts reported ~85% CRP reduction (a key inflammation marker), reinforcing clinical promise for MRT?8102 and sparking investor enthusiasm. Monte Rosa stock surges after positive data shows 85% CRP reduction
• Positive Sentiment: Analysts reacted to the clinical news with bullish moves — Guggenheim raised its PT to $34 and issued a Buy, and Wells Fargo raised its PT to $30 with an Overweight. These actions support upside from fundamentals if clinical progress continues. Benzinga
• Positive Sentiment: Zacks upgraded GLUE from Hold to Strong Buy amid the data-driven momentum, adding to short?term buyer interest. Zacks.com upgrade
• Neutral Sentiment: Several market watchers flagged GLUE as a “stock on the move,” highlighting momentum and technical strength that could attract momentum traders. Monte Rosa Therapeutics (GLUE) is on the Move
• Negative Sentiment: Monte Rosa priced an underwritten public offering to raise roughly $300 million: 11,125,000 shares at $24.00 plus 1,375,000 pre?funded warrants at $23.9999. The timing — immediately after a sharp rally — increases share supply and dilution risk, which likely weighed on the stock. Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.